WuXi Biologics Completes Biologics Mfg. Facility in Ireland

WuXi Biologics has completed the weather-tight seal of its biologics drug substance manufacturing facility on the Dundalk Campus in Ireland, marking the start of the company's global biomanufacturing network.

As one of the world's largest facilities using single-use bioreactors, this "Facility of the Future" began construction in February 2019 and completed the weather-tight seal of its main facility in December 2019. The facility is designed to adopt both large scale commercial manufacturing using disposable bioreactors and next-generation continuous bioprocessing manufacturing technology. It will have a total bioreactor capacity of 6,000 liters perfusion (MFG6) and 48,000 liters fed-batch (MFG7) after full completion.

"We are proud of achieving this great milestone 10 months after initiating the facility construction of our first global site in Europe, which is another testament of 'WuXi Bio Speed' implemented outside of China for the first time. Construction of our US facility will also begin soon as well." said Dr. Chris Chen, CEO of WuXi Biologics. "As a global company, we are building capabilities and capacities in the U.S., Europe and China to serve our clients and to benefit patients worldwide."

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.